It’s The AAF Exchange — your source for clear, data-driven insight into today’s economic and domestic policy issues.

In this episode of the AAF Exchange, AAF President Douglas Holtz-Eakin discusses Congress returning to face a federal-funding showdown, the Federal Reserve cautioning against declaring a “soft landing” victory, and the Biden Administration announcing the first round of drugs subject to Medicare price negotiation.

AAF products mentioned in today’s episode:

• In “Federal Budget PSA,” Holtz-Eakin reviews highlights of the latest debt, spending, and taxation data.
• In “Budget Chart Book – FY 2023,” Vice President for Economic Policy Gordon Gray compiled the latest fiscal data in an updated chart book.
• In “Highlights of CBO’s Long-Term Budget Outlook 2023,” Gray walks through the Congressional Budget Office’s newly updated Long-Term Budget Outlook.
• In “Is Fiscal Policy Driving the Economy (and Fighting the Fed)?” Holtz-Eakin examines whether federal spending – or fiscal policy more generally – contributes to near-term growth.
• In “Fitch Downgrades the U.S.,” Holtz-Eakin discusses Fitch’s downgrade of U.S. Treasury debt from AAA to AA+.
• In “Assessing the Economic Outlook,” Holtz-Eakin considers what the latest economic report tells us about the inflationary outlook.
• In “About That Recession,” Holtz-Eakin discusses Fed Chairman Jerome Powell’s speech at Jackson Hole, at which he delivered a firm “stay the course” message.
• In “About Those Long and Variable Lags,” Holtz-Eakin explores the impact of a San Francisco Fed research paper on upcoming Fed decisions.
• In “Setting the Record Straight,” Holtz-Eakin walks through four arguments against drug price negotiations.
• In “Just Exactly What Are We Supposed to Celebrate?” Holtz-Eakin explains why the IRA’s health provisions are nothing to celebrate.
• In “Video: Drug Pricing Provisions,” Holtz-Eakin reacts to President Biden’s announcement of the first 10 drugs subject to Medicare price negotiation under the IRA.
• In “Gross Price Controls and Net Effects,” Health Care Policy Analyst Jackson Hammond discusses President Biden’s announcement of the first 10 drugs subject to Medicare price negotiation under the IRA.
• In “The Special Pharmaceutical Relationship: A UK-U.S. Deep Dive on Setting the Best Price,” Director of Health Care Policy Laura Hobbs analyzes the potential consequences of the Inflation Reduction Act’s drug-price negotiations and the Medicaid Drug Rebate Program.
• In “The IRA After One Year,” Holtz-Eakin notes the Inflation Reduction Act’s lack of accomplishments on its first anniversary.
• In “The Inflation Reduction Act’s Drug Price Negotiations,” AAF experts provide a deep dive of the health provisions in the IRA since its passage. 

Whether you’re on your lunch break or commuting home, The AAF Exchange will keep you up to speed on today’s most pressing policy issues.

Subscribe on iTunes or Soundcloud, or listen at the link below.